Healthcare Global EnterprisesQ1 FY25

Healthcare Global Enterprises Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹575.6P/E: 216.4Market Cap: ₹8.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Q1 FY25 revenue at an all-time high of Rs. 526 crore, reflecting 17% growth YoY (adjusted for discontinued centers).
  • Established centers, excluding fertility business, grew 18% YoY with strong volume growth and improved realization.
  • Early Q2 performance strong, expected 14-15% growth QoQ, led by operational leverage.
  • Anticipated ongoing 13-15% revenue growth in existing hospitals for full year.
  • International business doubled compared to pre-COVID levels; focus on expanding markets in SAARC, Middle East, and Africa.
  • Acquisition of MG Hospital (Vizag) expected to boost consolidated revenue, expanding market share to 46% in region with 10-12% expected growth.
  • Emerging centers growing rapidly at 33% YoY; established centers growing at 14% YoY.
  • Improvements in Average Length of Stay (ALOS) and ARPOB (up 12% YoY) supporting volume and revenue expansion.
  • Expansion through Brownfield and new facilities, with CAPEX around Rs. 80 crores per quarter to support growth.

See what Healthcare Global Enterprises management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • Post-acquisition of Vizag, the company's debt will initially increase by Rs. 200 crores and later by another Rs. 150 crores after 18 months to complete an 85% acquisition.
  • The management plans to seek board approval at the appropriate time for a primary equity raise ("primary"), aimed at significantly reducing debt.
  • The exact size of the primary equity raise will be communicated when finalized.
  • The company intends to maintain its debt-to-equity ratio within internally accepted ranges, targeting a debt-to-EBITDA ratio of around 2.5x to 2.75x on a pre-Ind AS basis.
  • Currently, there are no mature inorganic acquisition opportunities under evaluation, but the company continues to assess strategic inorganic options.
  • CAPEX funding partly involves debt; Rs. 50 crores of the Rs. 80 crores CAPEX in Q1 was funded through debt, contributing to increased finance costs.
  • Overall, a primary equity raise is planned in the medium term to manage leverage following recent acquisitions.

See what Healthcare Global Enterprises management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Current quarter CAPEX was about Rs. 80 crores.
  • CAPEX for the rest of the year is expected to remain in a similar range (around Rs. 80 crores per quarter).
  • Investments are focused on Brownfield facilities and new facilities like Whitefield and North Bangalore.
  • Additional ROU of Rs. 200 crores related to new facilities in Ahmedabad and North Bangalore added.
  • Post-acquisition of Vizag-based Mahatma Gandhi Hospital, no immediate additional equipment CAPEX planned, as the hospital is well-equipped (robotic unit, PET scan, linear accelerators).
  • A new linear accelerator is being added to the Vizag center as part of the CAPEX.
  • Company aims to optimize operational efficiencies and synergies across hospitals to drive growth and cost management.

Track Healthcare Global Enterprises — get its next earnings analysis in your feed

How does Healthcare Global Enterprises rank vs peers in Healthcare Services?

Pro feature
ThisHealthcare Global Enterprises
Rev 3Mar 1

How does Healthcare Global Enterprises rank in Healthcare Services?

Compare Healthcare Global Enterprises against every Healthcare Services company (Q1 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →